Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitiglinide vs Nateglinide in Type 2 Diabetes
NCT00461617Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Aug 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of mitiglinide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Hemoglobin A1C at 20 weeks. Started Aug 2006; status: completed.
02
Drugs
mitiglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00461617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00461617.